Ceryx Medical has produced its first implantable bioelectronic pacemaker at the Manufacture of Active Implants and Surgical Instruments (MAISI) facility in London. It is also the first implantable device manufactured by the UK national facility since its opening in 2023. The Cardiff developer is investigating the technology as a potential heart failure treatment; the implant has yet to complete preclinical assessment and has not been approved for patient use.
Manufacture took place at the St Thomas’ MedTech Hub, where King’s College London operates MAISI with facilities for producing active implants and surgical instruments for clinical research. Established with UCL and Newcastle University through a £5.2 million Wellcome grant, the centre has two ISO-7 cleanrooms and a certified quality management system. Its equipment and regulatory support are intended for the small production runs needed before a complex medical device can be evaluated in humans.
An implant designed to remain inside the body imposes manufacturing requirements that extend beyond demonstrating that an electronic circuit functions. Controlled assembly, component traceability, documented production processes and appropriate verification help engineers establish which build conditions produced a particular unit. If a component or process later requires investigation, that evidence becomes important precisely because an implanted device cannot simply be retrieved and replaced like a bench prototype.
UK developers of complex active implants have historically needed to commission specialist overseas facilities for some early manufacturing stages. Transferring prototypes between design teams, production engineers and regulatory advisers can add iterations and make documentation more difficult to manage. MAISI brings regulated small batch manufacture and technical support into the same UK setting, although the availability of a facility does not remove the subsequent testing and authorisation requirements.
Ceryx’s device attempts to reproduce respiratory sinus arrhythmia, the normal variation in heart rate associated with breathing. The company describes its approach as biomimetic pacing because the stimulation pattern seeks to restore that relationship when it is disrupted in heart failure, rather than apply a fixed timing programme alone. Whether the implant can improve cardiac function or patient outcomes must be established by further studies; the manufacturing milestone provides no such result by itself.
The company previously completed its RSA-Pace clinical study, led by Professor Zaheer Yousef OBE, using an external pacing system to deliver the biomimetic pattern to patients. Results from that investigation have not yet been reported in full. Although the study provides a separate clinical research milestone, it does not demonstrate the implanted device’s safety, long-term reliability or treatment effectiveness. The manufactured implant is now entering preclinical tests before any further study designed to assess its clinical benefit.
Active implants combine electronic operation with the physical and biological constraints of implantation. Their design and manufacture may need to address electrical functionality, suitable encapsulation, mechanical durability and interactions with surrounding tissue. Ceryx and its partners have not disclosed the new pacemaker’s materials, dimensions, power architecture or validation results, so claims about battery life, service intervals or expected clinical performance would be premature.
Operating under a certified quality management system makes it possible to control and document specified build operations, including the handling of components and evidence of process consistency. The two ISO-7 cleanrooms provide a classified environment for sensitive manufacturing steps; they do not, by themselves, establish that a finished device is sterile or suitable for implantation. Those characteristics depend on device-specific design, materials, process validation and testing that have not been disclosed for the Ceryx implant.
MAISI supports the development of Class IIb and Class III devices, including active implants and complex surgical instruments, with dedicated assistance on UK regulatory requirements. A manufactured unit, a documented quality system and regulatory advice each contribute to clinical translation, but none substitutes for the evidence and permissions required to begin a clinical investigation. Commercial marketing authorisation would be another decision after the necessary evaluation, rather than an automatic consequence of successfully building a device.
Dr Stuart Plant, chief executive of Ceryx Medical, said: “Seeing the first implantable device come off the line is a moment the whole team has worked towards for years.” Ceryx has emphasised the importance of the UK manufacturing location. Professor Anne Vanhoestenberghe, professor of active implantable medical devices at King’s College London and MAISI director, said the facility had been established to help innovators manufacture devices to the standards required for clinical translation.
The pacing technology originates in research at the universities of Bristol, Bath and Auckland. Ceryx’s backers include BGF, Parkwalk Advisors and the Development Bank of Wales, while Professor Yousef has joined as chief medical officer. Those research, clinical and financial relationships support the programme’s development, but no production volumes, unit costs, implant lifetime or proposed commercial launch date have been confirmed.
Preclinical work will now test the newly manufactured implant before any proposed clinical assessment of its full benefit. The St Thomas’ facility has demonstrated that it can produce an active implant within its quality framework, fulfilling a practical early manufacturing objective. Ceryx must still establish how reliably the device operates and whether its intended physiological effect produces useful outcomes in patients with heart failure.
